KARLSRUHE, Germany, 30 June 2006. A recently published study shows that Euvegal® (Schwabe's proprietary Valerian/Melissa combination product) clearly improves pathological restlessness and insomnia in children under the age of 12. Therapeutic efficacy and tolerability were evaluated in a total of 918 children in this open, multicenter study.
KARLSRUHE, Germany, 28 April 2006. According to latest research, Dr. Willmar Schwabe Pharmaceuticals® proprietary phytomedicine is comparably effective as the standard synthetic drug tamsulosin in the treatment of benign prostatic hyperplasia (BPH) symptoms. The unique herbal combination product contains 160 mg WS® 1473 and 120 mg WS® 1031 (Schwabe's proprietary saw palmetto and nettle root extracts).
KARLSRUHE, Germany, 30 September 2005. A large placebo controlled study has again confirmed the efficacy of EGb 761® in typical dementia patients, where cognitive impairment is associated with neuropsychiatric symptoms such as depressed mood, anxiety, irritability and indifference.
KARLSRUHE, Germany, 8 July 2005. According to latest research, Dr. Willmar Schwabe Pharmaceuticals’ proprietary saw palmetto and nettle root extract combination is significantly superior to placebo in the treatment of lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).